Janux Therapeutics
La Jolla
About Janux Therapeutics
Janux Therapeutics develops immunotherapies that generate immune responses to prevent tumors and not affecting a patient’s healthy tissue. Janux technology targets all three stages of the anti-tumor immune response.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 101 – 250
- Estimated revenue: Less than $1M
- Total funding: $898.9M
- Funding stage: IPO
- Last round: Post-IPO Equity (Dec 2024)
- Ticker: nasdaq:JANX
- Website: januxrx.com
- Phone: 858-751-4493
Industries & Categories
Biotechnology, Health Diagnostics, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/janux-therapeutics-111396 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.